Cardiovascular morbidity and mortality in acromegaly-associated diabetes: a Swedish nationwide study
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgag322 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Angelo Milioto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, 413 46 Gothenburg, Sweden. Hauptthemen laut MEDLINE: Acromegaly, Cardiovascular Diseases, Diabetes Mellitus, Type 2. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ALF, Svenska Sällskapet för Medicinsk Forskning, Åke Wiberg Stiftelse, Göteborgs läkaresällskap.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Secondary diabetes mellitus occurs in 30% to 50% of patients with acromegaly despite a lean phenotype, whereas type 2 diabetes mellitus (T2DM) is associated with adiposity.
Objective
We compared mortality, morbidity, and treatment patterns between patients with acromegaly-associated diabetes (ACRO-DM) and T2DM.
Design
Nationwide, retrospective, matched-cohort study in Sweden.
Methods
The ACRO-DM group included patients with an acromegaly diagnosis in the Patient Register, with diabetes registered in the National Diabetes Register (NDR) or a dispensed glucose-lowering drug in the Prescribed Drug Register. Controls with T2DM from the NDR were matched 10:1 for sex, age, calendar year, and diabetes duration. We derived mortality and morbidity outcomes from the Death and Patient Registers.
Results
We included 348 patients with ACRO-DM and 3480 with T2DM. Mean (SD) age was 60.3 (13.2) and 59.5 (15.6) years, whereas diabetes duration was 2.8 (5.8) and 3.0 (7.1) years in ACRO-DM and T2DM, respectively. Baseline cardiovascular morbidity was more common in ACRO-DM than T2DM group (61% vs 43%), including hypertension (48% vs 29%), heart failure (11% vs 5%), arrhythmia (13% vs 9%), and stroke (8% vs 5%). The hazard ratio (HR) for overall mortality was 1.18 (95% CI, 0.96-1.46) in ACRO-DM compared with T2DM group. The ACRO-DM group had a higher risk of cardiovascular morbidity (HR = 1.55; 95% CI, 1.24-1.94), with increased hazards for venous thromboembolism, specifically pulmonary, and arrhythmia, whereas cardiovascular mortality was not increased (HR = 1.12; 95% CI, 0.78-1.60).
Conclusion
The risk of cardiovascular morbidity was increased in patients with ACRO-DM compared to T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, 413 46 Gothenburg, Sweden.
- Department of Endocrinology, Sahlgrenska University Hospital, 413 46 Gothenburg, Sweden.
- Wallenberg Center for Molecular and Translational Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden.
- Endocrinology Unit, Department of Internal Medicine and Medical Specialties, School of Medical and Pharmaceutical Sciences, University of Genova, 16132 Genoa, Italy.
- Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
- School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, 413 20 Gothenburg, Sweden.
ORCID-Profile: Angelo Milioto, Martin Adiels, Annika Rosengren, Gudmundur Johannsson, Daniela Esposito
Förderung
- ALF
- Svenska Sällskapet för Medicinsk Forskning, Åke Wiberg Stiftelse
- Göteborgs läkaresällskap
- Svenska Läkaresällskapet
- Swedish Research Council
- Swedish Heart and Lung Foundation
Zitieren
APA
Milioto, A., Ragnarsson, O., Ferone, D., Adiels, M., Smith, J. G., Rosengren, A., Johannsson, G., & Esposito, D. (2026). Cardiovascular morbidity and mortality in acromegaly-associated diabetes: a Swedish nationwide study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag322
Vancouver
Milioto A, Ragnarsson O, Ferone D, Adiels M, Smith JG, Rosengren A, et al. Cardiovascular morbidity and mortality in acromegaly-associated diabetes: a Swedish nationwide study. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag322
BibTeX
@article{Milioto2026,
author = {Milioto, Angelo and Ragnarsson, Oskar and Ferone, Diego and Adiels, Martin and Smith, J Gustav and Rosengren, Annika and Johannsson, Gudmundur and Esposito, Daniela},
title = {Cardiovascular morbidity and mortality in acromegaly-associated diabetes: a Swedish nationwide study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgag322}
}
EUVIMED